The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression. We show here that BRCA1 increases p53 protein levels through a post-transcriptional mechanism. BRCA1-stabilized p53 has increased sequence-speci®c DNAbinding and transcriptional activity. BRCA1 does not stabilize p53 in p14 ARF -de®cient cells. A deletion mutant of BRCA1 which inhibits p53-dependent transcription confers resistance to topoisomerase II-targeted chemotherapy. Our results suggest that BRCA1 may trigger the p53 pathway through two potentially separate mechanisms: accumulation of p53 through a direct or indirect induction of p14 ARF as well as direct transcriptional coactivation of p53. BRCA1 may also enhance chemosensitivity and repair of DNA damage through binding to and coactivation of p53.
Introduction
Hereditary breast carcinoma accounts for 5 ± 10% of all cases of breast cancer. BRCA1 mutations account for approximately 20 ± 50% of familial breast cancer depending on the population Miki et al., 1994; Easton et al., 1995) . Carriers of BRCA1 mutations have a 40 ± 80% risk of breast cancer and a 20 ± 40% risk of ovarian cancer during their lifetime. Genetic linkage studies identi®ed chromosome 17q as a locus for breast cancer susceptibility (Hall et al., 1990) . The BRCA1 gene was subsequently cloned and found to encode an 1863 amino-acid polypeptide . The amino-terminus of BRCA1 protein contains a RING ®nger domain whereas the C-terminus of BRCA1 contains an acidic domain suggestive of a role in transcriptional activation . About 90% of the mutations observed in the BRCA1 gene result in truncations, and the remainder of clinically relevant mutations are individual missense abnormalities that are scattered along the entire coding unit (Szabo and King, 1995) .
Eorts to understand the function of BRCA1 have uncovered links to transcriptional regulation and DNA recombination and/or repair. A role in transcriptional activation is supported by several observations: (1) the C-terminus of BRCA1, which is relatively acidic, can activate transcription when fused to a Gal4 DNAbinding domain (Chapman and Verma, 1996; Monteiro et al., 1996) ; (2) the N-terminus of BRCA1 contains a RING ®nger domain, which is found in a family of transcription factors and which may form a DNAprotein or protein-protein interaction site Lovering et al., 1993) ; (3) in transfection experiments, BRCA1 activates transcription from promoters containing p53 DNA-binding sites as well as from a p21 promoter lacking p53 DNA-binding sites Zhang et al., 1998; Ouchi et al., 1998) ; and (4) BRCA1 associates with the RNA polymerase II holoenzyme complex (Scully et al., 1997a) . The link between BRCA1 and DNA recombination and/or repair stems from the evidence that: (1) BRCA1 exists in a complex with Rad51, the human homologue of the E. coli RecA (Scully et al., 1997b) ; (2) BRCA1 and Rad 51 colocalize in spermatocytes along unsynapsed chromosomal segments and at the junction at which synapsis is occurring, as well as in S phase nuclear dot structures (Scully et al., 1997b) ; and (3) following exposure to DNA damaging agents, BRCA1 is hyperphosphorylated and disperses from dot structures and then dynamically accumulates at PCNA-containing replication or repair structures (Thomas et al., 1997; Scully et al., 1997c) . The functions of BRCA1 as a transcription regulatory protein as well as a protein involved in the DNA damage sensing and response pathway are not necessarily mutually exclusive. This hypothesis is further supported by the evidence that BRCA1 is a regulator of the tumor suppressor p53 (Zhang et al., 1998; Ouchi et al., 1998) .
BRCA1 can stimulate transcriptional activity of p53 from synthetic promoters containing multiple p53 DNA-binding sites as well as promoters of natural p53 target genes like p21 WAF1 , Bax and mdm-2 (Zhang et al., 1998; Ouchi et al., 1998) . In addition, BRCA1 can also activate transcription from a p21 WAF1 promoter reporter lacking p53 binding sites in cells which harbor mutant p53 and through a STAT-binding element within the p21 WAF1 promoter (Ouchi et al., 1998) suggesting p53-independent mechanisms of transcriptional activation by BRCA1. In this study, we carried out additional experiments to reproduce and further extend the observation that BRCA1 may activate transcription from the p21 WAF1 gene in a p53-independent manner. p53 and p21 WAF1 control important cell cycle checkpoints in response to DNA damage. BRCA1 and p53 proteins have the potential to interact and a truncation mutant of BRCA1 that retains the BRCA1-interacting region acts as a dominant negative inhibitor of p53-dependent transcription (Zhang et al., 1998; Ouchi et al., 1998) . However the mechanism by which BRCA1 stimulates p53-mediated transcription is not known.
We analysed the existence of both p53-dependent and independent mechanisms of transcriptional activation by BRCA1. Overexpression of BRCA1 resulted in accumulation of p53 with a comcomitant increase in sequence-speci®c DNA-binding and transcriptional activation by p53, which may provide an explanation for the stimulation of p53 transcriptional activity by BRCA1. Human cells lacking p14 ARF as well as p19 ARF -null MEF's do not stabilize p53 upon overexpression of BRCA1. In addition, cell lines which overexpress a deletion mutant of BRCA1 are partially defective for transcriptional activation by p53 and are more resistant to the topoisomerase II inhibitor etoposide. Our results provide a potential mechanism for BRCA1 regulation of the p53 pathway. The results also oer some insight into the consequences of expression of truncated BRCA1, as occurs commonly in familial breast cancer, namely a potentially decreased therapeutic response to topoisomerase II inhibition.
Results

BRCA1
activates the p21 promoter by p53-dependent and -independent mechanisms BRCA1 can activate transcription from the p21 promoter both by p53-dependent and -independent mechanisms Zhang et al., 1998; Ouchi et al., 1998) . In order to analyse this phenomenon further, we cotransfected the wild-type BRCA1 cDNA with the full-length p21 promoterluciferase reporter (WWP-LUC) into a variety of cell types carrying either endogenous wild-type or mutant p53 ( Figure 1A ). BRCA1 activated transcription from WWP-LUC in SW480 and Hela cells ( Figure 1A) . Because SW480 cells contain mutant p53 and Hela cells are phenotypically null for p53 due to the presence of the HPV E6 oncogene, this result suggests that a p53-independent mechanism may be involved in the activation of p21 promoter by BRCA1. However, BRCA1 is unable to activate transcription from the p21 promoter in the DLD1 colon cancer cell line ( Figure  1A ), which also carries mutant p53. This suggests that the ability of BRCA1 to activate transcription from the p21 promoter by a p53-independent mechanism may be a cell type speci®c phenomenon. BRCA1 also activated transcription from the p21 promoter in a variety of cell types all carrying wild-type p53: HCT116 (Colon carcinoma), HEPG2 (Hepatocellular carcinoma) and U2OS (Osteosarcoma) ( Figure 1A ).
BRCA1 activation of the p21 promoter in HCT116, HEPG2 and U2OS cells could be due either to a p53-dependent or to a p53-independent mechanism or both. In order to dierentiate between these possibilities, we cotransfected the wild-type BRCA1 cDNA with a p53-speci®c reporter (PG13-LUC). PG13-LUC is a synthetic promoter with 13 tandem copies of a p53 DNA-binding sequence cloned upstream of a basal polyoma promoter driving luciferase reporter expression only in the presence of wild-type p53 (El-Deiry et al., 1993) . BRCA1 did not activate transcription from PG13-LUC in SW480, Hela or DLD1 cells ( Figure  1B) , as expected because these cell lines do not contain wild-type p53. BRCA1 activated transcription from PG13-LUC in wild-type p53 containing HCT116, HEPG2 and U2OS ( Figure 1B) .
In order to further explore the p53-independent mechanism of transcriptional activation by BRCA1 in dierent cell lines, especially those carrying wild-type p53, we cotransfected the BRCA1 cDNA expression vector with a p21 promoter-reporter that lacks both upstream p53 DNA-binding sites (6-LUC). BRCA1 activated transcription from 6-LUC in HCT116, HEPG2 and U2OS ( Figure 1C ) con®rming the possible existence of a p53-independent mechanism in these cell lines in addition to the presence of the p53-dependent mechanism ( Figure 1B ). BRCA1 also activated transcription from 6-LUC in SW480 and Hela cells but not in DLD1 consistent with the presence of a p53-independent mechanism in these cell lines. In DLD1 cells, both the p53-dependent and -independent mechanisms of activation of transcription by BRCA1 are absent. It is of note that when wild-type p53 was expressed from transfected cDNA, BRCA1 was able to stimulate transcription from PG13-LUC in SW480 (mutant p53), SAOS-2 (p53 null) and p53 7/7 (MEF) (p53 null) cells. These observations indicate that the absence of functional p53 may be the primary reason for the absence of detectable BRCA1-activated p53-dependent transcription in these cell lines (Zhang et al., 1998) .
In order to further study the nature of the factor(s) involved in p53-independent activation by BRCA1, we utilized a fusion between HCT116 and DLD1 cells (Polyak et al., 1996) . We predicted that if DLD1 cells lack a factor necessary for p21 activation that this factor may be supplied in trans through the HCT116-DLD1 fusion, leading to reconstitution of transcription. Alternatively, if DLD1 cells contain an inhibitory factor, we predicted that it may function in a dominant fashion in the fusion to suppress transcription. The HCT116-DLD1 fusion cell line was transfected with wild-type BRCA1 and a p21 promoter lacking p53 DNA-binding sites (6-LUC). BRCA1 failed to activate transcription from 6-LUC (data not shown) suggesting the absence of p53-independent activation in the fusion cell line. This result may be due to the presence of an inhibitory factor in the fusion cell line presumably derived from the DLD1 cells, and which may represent the CtIP inhibitor of BRCA1-mediated transcription (Li et al., 1999) .
BRCA1 may have an eect on p53 protein levels, because these two proteins have been shown to interact (Zhang et al., 1998; Ouchi et al., 1998) . In order to determine the eect of BRCA1 on p53 protein levels, we cotransfected BRCA1 with p53 in SAOS-2 cells, which lacks p53. After 48 h, nuclear extracts were prepared and p53 levels were analysed by Western blotting. p53 levels increased in BRCA1 cotransfected cells (Figure 2A , compare lane 4 with 2). Because sequence-speci®c DNA-binding is required for p53 to activate transcription, we correlated the increased p53 protein levels with increased DNA binding ( Figure 2B , compare lane 9 with 5). In order to determine if BRCA1 has a similar eect on endogenous p53, BRCA1 was expressed from a replication de®cient adenovirus (Ad-BRCA1) by infecting wild-type p53-expressing HCT116 colon and H460 lung cancer cells. Cells infected with Ad-BRCA1 overexpressed BRCA1 protein as compared to Ad-LacZ infected cells ( Figure   3A ). Although the H460 cell line posseses a high basal level of BRCA1 protein, at least a twofold increase was observed upon infection with Ad-BRCA1. The overexpression of BRCA1 correlated with increased p53 and p21 protein levels as expected by immunoblotting ( Figure 3A ) and immunohistochemistry ( Figure 3B ). No change in p53 mRNA level was detected between Ad-LacZ and Ad-BRCA1 infected cells ( Figure 3C ). These results suggest that increased p53 protein levels and a subsequent increase in DNA-binding may contribute to the BRCA1-dependent stimulation of the transcriptional activity of p53.
The BRCA1-dependent increase in p53 protein levels involves ARF Figure 1 BRCA1 activates the p21 promoter by p53-dependent and -independent mechanisms. Cells as indicated were transfected with 1 mg of the reporter plasmids WWP-LUC (A), PG13-LUC (B) or 6-LUC (C) with either 2 mg of pCR3 (lane 1) or BRCA1 (lane 2) as described in Materials and methods. 9.5-LUC was used instead of 6-LUC for HCT116 cells . Cells were harvested 24 h or 48 h later and luciferase activity was measured as described in Materials and methods. The p53 status of the cell lines used is indicated above the graphs: m-mutant, deg-p53 is degraded due to E6 expression and w.t.-wild-type. PG13-LUC is a p53-speci®c, synthetic promoter with 13 tandem copies of a p53 DNA-binding sequence cloned upstream of a polyoma basal promoter (El-Deiry et al., 1993) . WWP-LUC contains 2.3 kb of the p21 WAF1 promoter with two p53 DNA-binding sites (ElDeiry et al., 1993 (ElDeiry et al., , 1995 . 6-LUC and 9.5-LUC contain 5' deletions of the p21 promoter at 7291 and 7117 respectively and both reporters lack p53-binding sites p53 stabilization by BRCA1 K Somasundaram et al number of positive growth regulatory proteins including c-myc, ras, E1A and E2F1 (Palmero et al., 1998; de Stanchina et al., 1998; Zindy et al., 1998; Bates et al., 1998) . We investigated whether ARF might also mediate p53 stabilization by BRCA1 since BRCA1 is required for embryonic cell proliferation (Hakem et al., 1996) . We compared the ability of BRCA1 to stabilize p53 in two human cell lines which dier in their p14 ARF status. The human melanoma cell line A375 lacks p14 ARF because of a deletion of exon 1b (Stone et al., 1995) and carries a wild-type p53 which can be activated by DNA damage (Stott et al., 1998) . In contrast, the human lung non-small cell carcinoma cell line H460 carries wild-type p14 ARF and p53. In H460, p53 protein levels were previously shown to be increased by both DNA damage and E1A delivered by adenovirus . The presence of wild-type p14 ARF in H460 cells has been con®rmed by PCR ampli®cation of exon 1b sequences (data not shown). As expected, adriamycin, a DNA damaging agent, stabilized p53 in both cell lines ( Figure 4A , panels k and l), while expression of E1A stabilized p53 in H460 ( Figure 4A , panel i) but not in A375 cells ( Figure 4A , panel j). BRCA1 overexpression did not result in increased p53 protein levels in A375 cells ( Figure 4A , panel e) as compared to H460 cells ( Figure 4A , panel f), suggesting a possible dependence on ARF.
We also analysed p53 protein levels by Western blotting following BRCA1 overexpression in H460 and A375 cells ( Figure 4B ). Adriamycin treatment resulted in decreased mobility of BRCA1, presumably due to phosphorylation as described previously (Thomas et al., 1997; Scully et al., 1997c) . p53 stabilization and p21 induction were observed in both cell lines following adriamycin exposure ( Figure 4B, lanes 5 and 10) . Overexpression of E1A resulted in p53 stabilization in H460 cells but not A375 cells ( Figure 4B , compare lane 4 with 9) consistent with the immunohistochemistry results ( Figure 4A , panels i and j). p53 stabilization by E1A did not result in p21 induction in H460 cells as shown previously . Infection with Ad-BRCA1 resulted in increased BRCA1 protein levels in both cell lines ( Figure 4B , lanes 3 and 8). However, BRCA1 increased p53 protein levels in H460 cells but not A375 cells ( Figure 4B , compare lane 3 with 8). As expected, p53 stabilization by BRCA1 also resulted in p21 induction in H460 cells ( Figure 4B, lane 3) . We tested the ability of BRCA1 to stabilize p53 in p19 ARF7/7 mouse embryo ®broblasts (MEF's). BRCA1 overexpression did not lead to increased p53 protein levels in p19 ARF7/7 cells ( Figure  5 , lane 3), while adriamycin exposure stabilized p53 protein ( Figure 5, lane 4) . These results suggest that ARF may be required for p53 stabilization by BRCA1.
Because our results suggest that p14 ARF may be required for p53 stabilization by BRCA1, we analysed the steady-state levels of p14 ARF mRNA under conditions where BRCA1 is overexpressed. Because p53 has been shown to negatively regulate the p14 ARF mRNA (Stott et al., 1998) , we analysed a null p53 cell line, Saos-2 cells for ARF expression following Ad-BRCA1 expression. Saos-2 cells infected with Ad-BRCA1 showed a twofold increase in p14 ARF mRNA levels as compared to the cells infected with Ad-LacZ (Figure 6 ), while Ad-E2F also caused an increase in p14 ARF mRNA, as previously shown (Bates et al., 1998) . These results suggest that p53 stabilization by BRCA1 may in part result from increased p14 ARF expression.
p53 is transcriptionally defective in cell lines expressing a dominant-negative mutant of BRCA1
The synthetic BRCA1 truncation mutant, BRCA1D500-1863, lacks both the Rad51-interacting domain and the C-terminal transactivation domain, but contains an intact amino-terminal domain with the potential to interact with p53. This mutant expresses a truncated BRCA1 protein as is common in familial breast cancer, and has been shown to act as a dominant inhibitor of p53-mediated transcription (Zhang et al., 1998) . It was hypothesized that cancer cells carrying mutant BRCA1 proteins may contain a defect in p53-mediated transcription (Zhang et al., 1998) . In order to further test this hypothesis, we generated stable cell clones expressing BRCA1D500-1863 and tested their ability to support p53-activated transcription. Colon cancer (SW480 and HCT116) or osteosarcoma (SAOS-2) cells were transfected with the control vector, pCR3 or the vector expressing truncated BRCA1, pCR3-BRCA1D500-1863 and resistant colonies were obtained following G418 selection. The expression of the exogenous truncated BRCA1 protein was con®rmed by Western blotting (Figure 7 ). Exogenously expressed p53 activated transcription from PG13-LUC eciently in the SW480/pCR3 clone while a 3 ± 5-fold reduction in p53-activated transcription was observed in three dierent SW480/BRCA1D500-1863 clones ( Figure  8A ). Similarly, p53 was less ecient in activating transcription in BRCA1D500-1863 clones of SAOS-2 ( Figure 8B ) and HCT116 ( Figure 8C ). These results con®rm that a truncation mutant of BRCA1 may reduce the transcriptional activity of p53.
Cells which express truncated BRCA1 are more resistant to the topoisomerase II inhibitor, Etoposide
We next determined whether the inhibition of p53-mediated transcription by truncated BRCA1 might alter sensitivity to anti-cancer therapy in vitro. We hypothesized that cells overexpressing truncated BRCA1 might have increased resistance to anticancer drugs. We assessed the chemosensitivity of HCT116 cells containing wild-type p53 and a stable integrated (Figure 9 ). Cell were treated with the drugs and the cell viability was measured by the MTT assay 4 days later. No apparent dierence was found between HCT116/pCR3 and HCT116/D500-1863 cell sensitivity to adriamycin or taxol ( Figure 9A,B) . However, HCT116/D500-1863 cells were found to be 50-fold more resistant to the topoisomerase II inhibitor etoposide as compared to HCT116/pCR3 cells ( Figure 9C,D) . It is not immediately obvious why HCT116/BRCA1D500-1863 cells are more resistant to etoposide but not to adriamycin or taxol. One possible explanation may be that adriamycin and taxol are less dependent on p53 or DNA repair in their killing eects and that inhibition of p53 function by truncated BRCA1 protein may in turn lead to increased resistance to DNA damaging agents such as etoposide.
Discussion
Our results con®rm that BRCA1 can activate transcription by both p53-dependent and independent mechanisms. The p53-independent transcriptional activation by BRCA1 appears to be cell-type speci®c. BRCA1 activated the p21 promoter in mutant p53-expressing SW480 and phenotypically p53-null Hela cells but not in mutant p53 expressing DLD1 cells. These results suggest that the p53-independent mode of activation of transcription by BRCA1 may involve additional factor(s). The DLD1-HCT116 cell fusion experiments argue that DLD1 cells may carry an inhibitory factor with respect to BRCA1-dependent p21 regulation such as CtIP (Li et al., 1999) . Although the cell lines used in these experiments do not represent cancers that BRCA1 has proven to act as a tumor suppressor, it is interesting to note that many of the cell lines used here derived from colon cancer tissue, a tumor type that has been found to both harbor deletions of BRCA1 and occur in a slightly higher incidence in the presence of BRCA1 mutations (Garcia-Patino et al., 1998) . BRCA1 signi®cantly activated transcription in a p53-dependent manner in all human cell lines tested except for p14 ARF -de®cient A375 cells, where the INK4a/ARF locus is abnormal. p53-dependent transcriptional activation by BRCA1 was observed in cell lines that carry mutant p53 (SW480) or lack p53 (SAOS-2 and p53 7/7 MEF) when exogenous wild-type p53 was introduced by transfection. BRCA1 also stimulated transcription from the Bax and mdm-2 promoters in a p53-dependent fashion (Zhang et al., 1998; Ouchi et al., 1998) . The results suggest that BRCA1 can in¯uence p53 function by stimulating its transcriptional activity through a intermediary step involving the ARF gene product. We found that the overexpression of BRCA1 resulted in a several fold increase in p53 protein levels. Increased p53 protein was correlated with a concomitant increase in sequence-speci®c DNA-binding by p53 protein and increased transcriptional activation as measured by the induction of p21 protein. These results suggest that increasing the stability of the p53 may underline the mechanism by which BRCA1 coactivates p53-mediated transcription. p19 ARF (p14 ARF in human) is involved in p53 stabilization in response to oncogenic signals from E1A, ras and c-myc (Palmero et al., 1998; de Stanchina et al., 1998; Zindy et al., 1998) . E2F-1 was found to transcriptionally activate p14 ARF , which linked oncogenic signals from E1A, ras and c-myc to p14 ARF and then to p53 (Bates et al., 1998) . However, p19
ARF does not mediate the activation of p53 by DNA damage, which appears to involve ATM and possibly DNA-PK dependent alterations in p53 phosphorylation and protein stability (see El-Deiry, 1998 for review). Our results suggest that BRCA1 stabilizes p53 in a p14 ARFdependent manner. We found that in p14 ARF7/7 MEFs, BRCA1 could not induce an accumulation of p53 ± unfortunately, replacement of p14 ARF into these cells to see a reverse of the phenotype was not possible. Reintroduction of p14 ARF alone is able to stabilize p53 protein (Stott et al., 1998) , therefore a speci®c eect of BRCA1 would not be able to be seen. BRCA1 also increases the levels of p14 ARF mRNA although this may or may not be a direct eect. These results suggest that BRCA1 may act through the p53 protein either by directly coactivating p53-dependent transcription (Zhang et al., 1998) or by inducing accumulation of p53 protein by induction of the p14 ARF protein. It is of interest that BRCA1, which is a tumor suppressor, utilizes a signaling pathway common to several positive regulators of growth. Members of the E2F transcription factor family are positive regulators of cell cycle progression (La Thangue, 1994; Adams and Kaelin, 1995; Weinberg, 1995) . However, the E2F1 knockout studies in mice suggest that E2F1 may act as a suppressor of cell proliferation (Field et al., 1996) . Similarly, murine BRCA1 knockout studies suggested that the BRCA1 tumor suppressor may be required for embryonic cell proliferation (Hakem et al., 1996) . A BRCA1 deletion mutant which lacks both the Rad51-interacting domain and the C-terminal transcriptional activation domain was unable to coactivate p53 transcription activity and also inhibited p53-mediated transcription when overexpressed (Zhang et al., 1998) . It was suggested that cancer cells carrying mutant BRCA1 proteins may be defective for p53-mediated transcription (Zhang et al., 1998) . We tested this hypothesis by generating stable cell lines which overexpress the truncated dominant negative BRCA1 (BRCA1D500-1863). We found that the stable clones of BRCA1D500-1863 from three dierent cell types were partially defective for p53 transcriptional activity. It is of interest to note that a novel class of p53 mutants with a defective transformation capability is selected in BRCA1-associated tumors (Smith et al., 1999) . Because a BRCA1 mutant inhibits transcriptional activation by p53, we hypothesized that cell lines carrying the dominant negative deletion mutant of BRCA1 may be more resistant to chemotherapy. We found that a stable clone of the HCT116 cell line expressing the dominant negative truncation deletion mutant of BRCA1 was 50-fold more resistant to etoposide, but not to adriamycin or taxol as compared to the vector control stable clone. These results predict that the presence of truncated BRCA1 may lead to increased resistance to topoisomerase II directed therapy. It is possible that cells which carry truncated BRCA1 proteins may be more resistant to chemotherapeutic agents that rely on the p53 pathway for apoptosis or DNA repair.
Material and methods
Cell lines and plasmids
The culture conditions of SW480, HCT116, H460, HEPG2, U2OS, Hela and SAOS-2 cells were previously described (Zhang et al., 1998; Zeng et al., 1997) . A375 and DLD1 were obtained from ATCC. p19 ARF7/7 MEF cells were obtained from Drs Martine Roussel and Charles Sherr (St. Jude). The luciferase reporter plasmids pG13-LUC and WWP-LUC were described previously (El-Deiry et al., 1993) . 6-LUC and 9.5-LUC contain 5' deletions of the p21 promoter at 7291 and 7117 respectively and both of them lack p53-binding site . pCEP4, pCEP4/p53, pCR3 and pCR3/ BRCA1, pCR3/BRCA1D500-1863 were described previously (Zhang et al., 1998) . The DLD1-HCT116 fusion cell line was described before (Polyak et al., 1996) .
Transfections and reporter assays SW480, HCT116, HEPG2, U2OS, and DLD1 cells were transfected as described (Zhang et al., 1998) . Hela and SAOS-2 cells were transfected using the calcium phosphateprecipitation method (Somasundaram et al., 1996) . Cells were harvested after 24 h in cases where lipofectin or lipofectamine was used or 48 h in cases where calcium phosphate was used and luciferase assays were carried out as described . Stable cell lines expressing the dominant negative truncation mutant of BRCA1 were made as follows: SW480, SAOS-2 and HCT116 cells (0.5610 6 cells) were transfected with either pCR3 or pCR3/BRCA1D500-1863 (2 mg). After 24 h, cells were harvested and seeded few cells per well with G418 (500 mg/ml) in 24-well plates. The medium was changed once every 3 days. Wells with single colonies were chosen and cells from those wells were expanded and analysed for the expression of truncated BRCA1 protein by Western blotting.
Adenovirus reagents and infections
Ad-LacZ and Ad-p53 (El-Deiry et al., 1993) were obtained from B Vogelstein (Johns Hopkins University). Ad-E1A was provided by Stanley Bayley (McMaster University) and used as described . The BRCA1 cDNA was released from pCR3/BRCA1 and subcloned as a blunt end fragment into E1 and E3 deleted recombinant adenovirus (Quantum Biotechnologies, Montreal) as described previously (Katayose et al., 1995) . All viruses were propagated, titered and infected at 50 MOI as described .
Gelshift assay, Western blotting and immunohistochemistry
Preparation of nuclear extracts and gelshift assays for p53, using oligonucleotides corresponding to p53 binding site #1 of the p21 WAF1 promoter (El-Deiry et al., 1995) were performed as described . Western blotting was carried out as described ) using mouse antihuman p53 monoclonal (Ab-2; Oncogene Sciences), mouse anti-human BRCA1 monoclonal (Ab-1; Oncogene Sciences), mouse anti-human p21 monoclonal EA10 (Ab-1; Oncogene Sciences), mouse anti-E1A monoclonal M73 (Ab-1; Oncogene Sciences), rabbit anti-human actin polyclonal (I-19; Santa Cruz). Immunohistochemical detection of p53 and p21 WAF1 proteins was carried out using DO7 mouse anti-human p53 monoclonal (Novacastra) and mouse anti-human p21 WAF1 monoclonal EA10 (Ab-1; Oncogene Sciences) as previously described (El-Deiry et al., 1995) . The chemotherapeutic agents adriamycin, taxol and etoposide were used at concentrations described in the Figures or Figure legends .
Northern blotting
Total RNA isolation and Northern blotting were carried out as previously described (El-Deiry et al, 1993) . A BamHI fragment of 1.7 kb in size from the plasmid SN3 carrying the human p53 cDNA was used as a probe for p53 on Northern blots (Baker et al., 1990) . For the p14 ARF Northern blot, a PCR ampli®ed fragment of 190 bps corresponding to the coding sequence of exon 1b of p14 ARF was used as a probe. The primers used were 5'-CATGGTGCGCAGGTTCTT-3' and 5'-CTTCTAGGAAGCGGCTGC-3'.
MTT assay
Cell viability was measured by the MTT assay after 4 days of drug treatment as a measure of chemosensitivity as described (Blagosklonny and El-Deiry, 1996) .
